secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0001493152-23-008489
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 4.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma enters research agreement with Georgetown for HDAC6 inhibitor SP-2-225
--------------------------------------------------------------------------------

- Research agreement with Georgetown University for up to $128,400 to test SP-2-225 in breast cancer model.
- Agreement runs April 1, 2023 to March 31, 2024; supports IND-enabling studies in 2023.
- Plans to submit IND and start Phase I clinical trial for SP-2-225 in 2024.
- Auditor changed from BF Borgers CPA PC to FORVIS LLP effective March 21, 2023; no disagreements.
- Going concern opinion from 2021 resolved after $11.4M IPO and $4.0M private placement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315223008489/0001493152-23-008489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315223008489/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-008489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer